Related by context. All words. (Click for frequent words.) 77 neoadjuvant chemotherapy 74 preoperative chemotherapy 74 adjuvant radiotherapy 74 nab paclitaxel 73 postoperative chemotherapy 73 neoadjuvant therapy 73 neoadjuvant treatment 73 adjuvant radiation 73 chemoradiotherapy 72 adjuvant chemotherapy 72 chemoradiation 71 Doxil ® 70 androgen deprivation 70 metastatic RCC 70 Neoadjuvant 70 EBRT 70 pCR 70 heavily pretreated patients 70 chemoradiation therapy 69 lymphadenectomy 69 adjuvant therapy 69 locoregional recurrence 69 fallopian tube cancers 69 biochemical relapse 69 renal tumors 69 pegylated liposomal doxorubicin 69 curative resection 69 nonmetastatic 69 resectable 69 locoregional 69 cytoreduction 69 concurrent chemoradiation 69 taxane therapy 69 ABVD 69 estramustine 69 androgen suppression 69 paclitaxel carboplatin 69 stage IIIB 69 operable breast cancer 68 bendamustine 68 external beam radiotherapy 68 clinically localized prostate 68 histologically confirmed 68 cystectomy 68 debulking surgery 68 relapsed MM 68 docetaxel chemotherapy 68 pertuzumab 68 mycophenolate mofetil 68 adjuvant tamoxifen 68 biochemical recurrence 68 NSABP B 68 androgen independent 68 gemcitabine Gemzar 68 metastatic renal cell carcinoma 68 recurrent NSCLC 68 bevacizumab Avastin ® 68 gemcitabine Gemzar ® 68 carboplatin paclitaxel 68 Flu Cy 67 medically inoperable 67 prostate carcinoma 67 cisplatin gemcitabine 67 pancreatic adenocarcinoma 67 radiotherapy RT 67 NMIBC 67 FOLFOX4 67 cytoreductive nephrectomy 67 Platinol ® cisplatin 67 gemcitabine carboplatin 67 pegylated interferon alfa 2b 67 stage IIIb IV 67 sustained virological response 67 endometrial carcinoma 67 LHRH receptor positive 67 cytoreductive surgery 67 colorectal liver metastases 67 decitabine 67 ZACTIMA 67 nephrectomy 67 chemoembolization 67 metastatic GIST 67 relapsed ovarian cancer 67 F FDG PET 67 papillary renal cell carcinoma 67 adriamycin 67 adecatumumab 67 hepatic resection 67 recurrent glioblastoma multiforme 67 CR nPR 66 antiangiogenic therapy 66 liver resection 66 radiochemotherapy 66 preoperative radiotherapy 66 KRAS mutations occur 66 FOLPI 66 nephron sparing surgery 66 TACE 66 epirubicin 66 chemotherapeutic regimens 66 HER2 positive metastatic breast 66 tumor lysis syndrome 66 lymph node dissection 66 pelvic lymphadenectomy 66 platinum refractory 66 FOLFIRI 66 prostate cancer CaP 66 vinorelbine 66 Taxotere ® 66 trastuzumab 66 XELOX 66 radical prostatectomy RP 66 RECIST Response Evaluation Criteria 66 DAPT 66 sorafenib Nexavar 66 lymph node involvement 66 ixabepilone 66 viral kinetics 66 FOLFOX 66 recurrent GBM 66 metastatic HRPC 66 dacarbazine 66 fallopian tube carcinoma 66 dose dexamethasone 66 plus prednisone 66 dose cytarabine 66 lymph node metastases 66 doxorubicin cyclophosphamide 66 5-fluorouracil/leucovorin 66 MGd 66 radical nephrectomy 66 severe neutropenia 66 metastatic castration resistant 66 melphalan prednisone 66 epirubicin cyclophosphamide 66 chlorambucil 66 EURIDIS 66 recurrent prostate cancer 66 paclitaxel eluting stents 66 virologic failure 66 capecitabine Xeloda 66 non squamous NSCLC 66 APTIVUS r 66 underwent resection 66 surgical debulking 66 doxorubicin docetaxel 66 oblimersen 66 radical cystectomy 66 receptor tyrosine kinase inhibitor 66 evaluable 65 CCyR 65 goserelin 65 sentinel lymph node biopsy 65 plus dexamethasone 65 heavily pretreated 65 gefitinib Iressa 65 daunorubicin 65 sirolimus eluting stents 65 anthracycline taxane 65 MAGE A3 ASCI 65 tumor recurrence 65 hepatic metastases 65 recurrent metastatic 65 prospectively defined 65 relapsed refractory multiple myeloma 65 lenalidomide dexamethasone 65 transurethral resection 65 Pemetrexed 65 distant metastasis 65 RTOG 65 tumor necrosis 65 liver metastasis 65 mRCC 65 5FU 65 brain metastases 65 tamoxifen therapy 65 cisplatin chemotherapy 65 Bezielle 65 alvespimycin 65 cilengitide 65 sunitinib malate 65 primary percutaneous coronary 65 gemcitabine 65 xenograft models 65 docetaxel Taxotere 65 ribavirin RBV 65 CA4P 65 nodal metastases 65 Irinotecan 65 ritonavir boosted 65 FDG PET 65 multicentre randomized 65 mg/m2 dose 65 postoperative radiotherapy 65 distant metastases 65 PEG IFN 65 BEACOPP 65 BCIRG 65 ipsilateral breast 65 CALGB 65 pT2 65 #mg QD [002] 65 allogeneic stem cell 65 cisplatin 65 tumor resection 65 metastatic malignant 65 HGPIN 65 epithelial ovarian cancer 65 Kaplan Meier analysis 65 erlotinib Tarceva ® 65 Free Survival PFS 65 IV NSCLC 65 oral rivaroxaban 65 #mg/m# [002] 64 parathyroidectomy 64 ASCT 64 Xelox 64 low dose cytarabine 64 unresectable stage 64 recurrent malignant glioma 64 telaprevir dosed 64 androgen suppression therapy 64 multicenter randomized controlled 64 liver metastases 64 Gemcitabine 64 bevacizumab Avastin 64 darunavir ritonavir 64 tanespimycin 64 5 FU leucovorin 64 autologous SCT 64 PSA nadir 64 PCa 64 breast carcinoma 64 EUS FNA 64 genotypic resistance 64 adjuvant therapies 64 pneumonectomy 64 FDG-PET/CT 64 evaluable patients 64 progression TTP 64 nodal metastasis 64 receiving highly emetogenic 64 cytotoxic chemotherapy 64 flutamide 64 Lenalidomide 64 β blockers 64 ELOXATIN 64 KRAS status 64 everolimus eluting stents 64 antithymocyte globulin 64 VELCADE melphalan 64 rFVIIa 64 DOXIL 64 nonmetastatic prostate cancer 64 chemotherapy cisplatin 64 salpingo oophorectomy 64 randomized multicenter trial 64 gemcitabine chemotherapy 64 liver transplant recipients 64 DMARD 64 Pegylated Liposomal Doxorubicin 64 trials RCTs 64 relapsed SCLC 64 refractory AML 64 idarubicin 64 metastatic hormone refractory 64 randomized Phase III 64 biliary tract cancer 64 fosbretabulin 64 allogeneic SCT 64 nonrandomized 64 CHOP chemotherapy 64 cyclophosphamide methotrexate 64 evaluable subjects 64 fluoropyrimidine 64 Ceplene/IL-2 64 vandetanib 64 CIMZIA ™ 64 Adjuvant chemotherapy 64 lymph node metastasis 64 liposomal doxorubicin 64 registrational Phase 64 HSCT 64 dosage regimens 64 placebo controlled clinical 64 baseline LDH 64 Accelerated Partial Breast Irradiation 64 alfa 2a 64 oral ridaforolimus 64 azacitidine 64 elacytarabine 64 cytogenetic response 64 temsirolimus 64 crizotinib PF # 64 paclitaxel Taxol 64 fluvastatin 64 infusional 64 paclitaxel poliglumex 64 EGFR TKI 64 Platinol ® 64 prospective multicenter 64 PSADT 64 trabectedin 63 underwent surgical resection 63 sipuleucel T 63 GnRH agonist 63 Trastuzumab 63 paricalcitol 63 mCRC patients 63 Response Evaluation Criteria 63 interferon alfa 2b 63 androgen ablation 63 definite stent thrombosis 63 remission CR 63 remission induction 63 assessing T DM1 63 NATRECOR ® 63 BR.# 63 paclitaxel cisplatin 63 peginterferon 63 dalteparin 63 CR CRu 63 glycoprotein IIb IIIa inhibitors 63 etoposide 63 weekly subcutaneous injections 63 epoetin alpha 63 Myocardial Infarction Study 63 metastatic CRC 63 partial remissions 63 imatinib Gleevec 63 HCV SPRINT 63 5-FU/LV 63 GnRH agonists 63 tumor histology 63 carotid endarterectomy CEA 63 micrometastases 63 node dissection 63 trastuzumab Herceptin R 63 periprocedural 63 daily subcutaneous injections 63 8mg/kg 63 ALND 63 pomalidomide 63 PSMA ADC 63 refractory NSCLC 63 prognostic factors 63 phase IIb clinical 63 adenoma recurrence 63 Pegasys plus Copegus 63 Amrubicin 63 undetectable HBV DNA 63 5 fluorouracil leucovorin 63 dasatinib Sprycel ® 63 unresectable 63 pT3 63 neratinib 63 node metastases 63 urothelial carcinoma 63 Radical prostatectomy 63 advanced adenomas 63 CIMZIA TM 63 pemetrexed 63 low dose dexamethasone 63 Pertuzumab 63 BCG refractory 63 comparator arm 63 ovarian carcinoma 63 OPAXIO 63 ExTRACT TIMI 63 cetuximab 63 tumor shrinkage 63 myeloablative 63 composite endpoint 63 STRIDE PD 63 HBeAg positive patients 63 Events MACE 63 BRCA2 mutation carriers 63 hematologic toxicity 63 anastrazole 63 sentinel node biopsy 63 BRIM2 63 antitumor effect 63 adjuvant cisplatin 63 fluorouracil 63 follicular NHL 63 eribulin mesylate 63 sunitinib 63 tirofiban 63 FOLFOX regimen 63 intravenous bisphosphonates 63 hypofractionated 63 total thyroidectomy 63 refractory CLL 63 noninferior 63 Tarceva TM 63 specific antigen PSA 63 Mitomycin C 63 cisplatin vinorelbine 63 anastrozole 63 Pharmacokinetics PK 63 HER2 negative 63 bladder carcinoma 63 luteinizing hormone releasing 63 HER2 positive cancers 63 platelet inhibitor 63 PegIFN RBV 63 #mg/m# [001] 63 epithelial tumors 63 castrate resistant prostate cancer 63 cyclophosphamide 63 orchiectomy 63 K ras mutations 63 chemotherapy docetaxel 63 Paraplatin ® 63 gadolinium enhanced 63 hepatocellular carcinoma 63 situ CIS 63 neo adjuvant 63 unresectable tumors 63 oral clodronate 63 prostate cancer HRPC 63 PREZISTA r 63 esophagectomy 63 NCCTG N# 63 Degarelix 63 docetaxel 63 alkylating agent 63 systemic ALCL 63 interferon alfa 2a 63 complete cytogenetic 63 Fludara 63 FOLFOX6 63 5 Fluorouracil 63 ribavirin Copegus ® 63 Folfox 63 thromboembolic events 63 CLL SLL 63 HBeAg negative patients 63 trastuzumab Herceptin ® 63 Ophena TM 63 fulvestrant 63 EGFR HER2 63 T1c 63 interferon ribavirin 63 subanalysis 63 lymphocytosis 63 autologous stem cell 63 LEXIVA r 63 irinotecan chemotherapy 63 PEGylated interferon beta 1a 63 plus gemcitabine 63 intraperitoneal chemotherapy 63 DLTs 63 RRMS patients 63 Subgroup analysis 62 irbesartan 62 pain palliation 62 novel VDA molecule 62 demonstrated antitumor activity 62 metastatic pancreatic 62 Fulvestrant 62 hepatocellular carcinoma HCC 62 biologic DMARD 62 dacarbazine DTIC 62 FASLODEX 62 HER2 expression 62 sorafenib tablets 62 antithrombotic therapy 62 intravesical therapy 62 dose cohort 62 Zevalin consolidation 62 HuMax EGFr 62 KRAS wild 62 HER2 overexpression 62 CTAP# Capsules 62 endothelin antagonists 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 TOP2A 62 GOUT 62 contralateral breast 62 peginterferon alfa 2b 62 advanced adenoma 62 mg kg dose 62 prostate cancer AIPC 62 CRp 62 abacavir lamivudine 62 castrate resistant 62 ARIMIDEX 62 Combination therapy 62 Elitek 62 stage IIIA 62 CYT# potent vascular disrupting 62 dasatinib 62 liposomal amphotericin B 62 sorafenib Nexavar ® 62 DMARD therapy 62 GP IIb IIIa inhibitors 62 haematologic 62 invasive carcinoma 62 letrozole Femara 62 achieved ACR# 62 Panzem R NCD 62 topotecan 62 Recurrence Score 62 Hormone Refractory Prostate Cancer 62 Acute Ischemic Stroke 62 EFAPROXYN 62 NSABP 62 clinicopathological features 62 advanced hepatocellular carcinoma 62 TAXOTERE R 62 LUX Lung 62 Surgical resection 62 radical prostatectomy 62 superficial bladder cancer 62 endometrial hyperplasia 62 colorectal adenoma 62 hepatectomy 62 olaparib 62 AVADO 62 Imprime PGG 62 splenectomized patients 62 inhibitor RG# 62 asymptomatic metastatic 62 urothelial cancer 62 allogeneic hematopoietic stem cell 62 Group RTOG 62 paclitaxel Taxol ® 62 carboplatin 62 Thrombolysis 62 ELACYT 62 Xanafide 62 antiretroviral naïve 62 metastatic malignant melanoma 62 HoLEP 62 bone metastasis 62 advanced unresectable 62 neurologic progression 62 q#h 62 mapatumumab 62 pulmonary metastases 62 metastatic gastric 62 multivariate analyzes 62 Gliadel Wafer 62 evaluating tivozanib 62 eplerenone 62 paclitaxel Taxol R 62 axillary dissection 62 dose melphalan 62 chemo radiotherapy 62 alpha 2a 62 IIIa inhibitor 62 VADT 62 pharmacodynamic PD 62 Chemoradiation 62 elective PCI 62 Allovectin 7 ® 62 EVEREST II 62 peritoneal carcinomatosis 62 nadolol 62 temozolomide TMZ 62 undergone radical prostatectomy 62 adjuvant trastuzumab 62 secondary efficacy endpoints 62 treatment naive genotype 62 refractory chronic lymphocytic 62 PegIFN 62 EGFR mutation positive 62 galiximab 62 CYPHER Stent 62 gemcitabine cisplatin 62 multivariate Cox 62 contralateral breast cancer 62 oncologic outcomes 62 ER CHOP 62 TMC# C# 62 Solid Tumors 62 VATS lobectomy 62 perioperative complications 62 Faslodex 62 depsipeptide 62 Peginterferon 62 strontium ranelate 62 ALA PDT 62 Proxinium TM 62 unfractionated heparin UFH 62 hormone receptor positive 62 methotrexate monotherapy 62 ongoing Phase 1b 62 subgroup analyzes 62 immunohistochemical 62 liposomal formulation 62 drug eluting stent implantation 62 prostate cancer CRPC 62 dose escalation phase 62 androgen blockade 62 vorinostat 62 TTF Therapy 62 coinfected patients 62 virological response 62 prostate TURP 62 platelet reactivity 62 cranial radiation 62 scintigraphic 62 bevacizumab 62 somatostatin analog 62 dexamethasone Decadron 62 tenecteplase 62 graft occlusion 62 recurrent VTE 62 fibrinolytic 62 coronary revascularization 62 histologically proven 62 APPRAISE 62 ErbB2 positive 62 Peg IFN 62 invasive bladder 62 BENICAR HCT 62 hydroxymethyl coenzyme 62 complete cytogenetic response 62 Sorafenib 62 Metastatic Prostate Cancer 62 lipid lowering drugs 62 docetaxel prednisone 62 imatinib therapy 62 symptomatic VTE 62 tamoxifen Nolvadex ® 62 plus ribavirin 61 TORISEL 61 localized renal 61 relapsing multiple sclerosis 61 clinicopathological 61 sarcomatoid 61 octreotide LAR 61 previously untreated follicular 61 metastatic neuroendocrine tumors 61 immunosuppressive regimen 61 RECIST criteria 61 riociguat 61 CYP#D# inhibitor 61 patients evaluable 61 CLARITY study 61 Subgroup analyzes 61 CR# vcMMAE 61 XIENCE V demonstrated 61 lenalidomide Revlimid R 61 Intravenous CP 61 Cloretazine 61 rFSH 61 conventional angiography 61 endosonography 61 KRAS mutations 61 hA# 61 refractory multiple myeloma 61 partial nephrectomy 61 EOquin TM 61 response CCyR 61 pheochromocytoma 61 nondiabetic patients 61 carotid artery stenting 61 #F FDG 61 oral Xeloda 61 taxane resistant 61 relapsed myeloma 61 immunoconjugate 61 orthotopic 61 thromboembolic 61 placebo dexamethasone 61 urothelial bladder cancer 61 insulin detemir 61 autologous chondrocyte implantation 61 Capecitabine 61 teriflunomide 61 axillary nodes 61 resectable pancreatic cancer 61 refractory acute myeloid 61 TNF blocker therapy 61 viral kinetic 61 Afatinib 61 ZYBRESTAT fosbretabulin 61 postintervention 61 Cyclophosphamide 61 prospective randomized controlled 61 lymphoid malignancies 61 fludarabine cyclophosphamide 61 seminoma 61 fondaparinux 61 histologies 61 active comparator 61 prostate cancer mCRPC 61 FOLFOX chemotherapy 61 KRAS mutation 61 nodal dissection 61 chemoresistant 61 dasatinib Sprycel 61 #F FDG PET 61 ganetespib 61 ribavirin therapy 61 differentiated thyroid 61 Randomized controlled 61 prospectively randomized 61 immunomodulatory therapy 61 carotid artery stenting CAS 61 CD3 monoclonal antibody 61 retroperitoneal 61 6 mercaptopurine 61 sorafenib 61 saline placebo 61 nonoperative 61 intratumoral injection 61 intravesical 61 squamous histology 61 certolizumab 61 #Gy 61 AVASTIN 61 axitinib 61 metastatic colorectal 61 epithelial ovarian 61 standard chemotherapy regimen 61 COPERNICUS 61 patients undergoing percutaneous 61 Platinol 61 clodronate 61 bortezomib 61 eribulin 61 mucinous 61 anti leukemic 61 intradermal injections 61 double blinded randomized 61 recurrent glioblastoma 61 pancreatic neuroendocrine tumors 61 hypercalcemia 61 lung metastases 61 unstable angina UA 61 leukemia AML 61 melphalan 61 lapatinib Tykerb 61 azathioprine 61 PREVENT IV 61 TO AVOID PREGNANCY WHILE 61 binary restenosis 61 castration resistant prostate cancer 61 chemosensitivity 61 symptomatic BPH 61 completely resected 61 univariate 61 RE LY 61 Natalizumab 61 hENT1 61 intravesical chemotherapy 61 virologic response 61 ibandronate 61 Torisel 61 MabCampath 61 adalimumab 61 anthracycline containing 61 thalidomide Thalomid 61 Vidaza ® 61 cetuximab Erbitux ® 61 microwave hyperthermia 61 sunitinib Sutent 61 Pegylated Interferon 61 transplant ASCT 61 mg m² 61 refractory metastatic 61 #mg BID [003] 61 refractory prostate cancer 61 interferon alfa 61 gefitinib 61 antiangiogenic agent 61 docetaxel Taxotere ® 61 patients undergoing CABG 61 Randomized Phase II 61 mcg BID 61 metastatic castrate resistant 61 ipsilateral stroke 61 ug dose 61 esophageal carcinoma 61 intact parathyroid hormone 61 ATACAND 61 metastatic lesions 61 R# #mg BID 61 Stenting Trial CREST 61 Vectibix monotherapy 61 underwent radical prostatectomy 61 STEMI patients 61 ACTEMRA TM 61 tocilizumab 61 anti angiogenic therapy 61 rosuvastatin #mg 61 selective modulator 61 Traficet EN 61 Metastatic Renal Cell Carcinoma 61 complete remissions 61 huN# DM1 61 Prospective Randomized 61 trastuzumab DM1 61 folinic acid 61 adjuvant endocrine therapy 61 SLN biopsy 61 CsA 61 XIENCE V PROMUS Stent 61 Capesaris 61 prostate cancer PCa 61 imetelstat 61 FUSILEV enhances 61 EORTC 61 Follicular Lymphoma 61 locoregional disease 61 evaluating REVLIMID 61 hematopoietic cancers 61 mitomycin 61 Adjuvant Therapy 61 Panzem NCD 61 TRUS 61 AVOREN 61 duplex ultrasonography 61 sirolimus eluting stent 61 Fludarabine 61 prognostic indicators 61 radiation chemoradiation 61 Bevacizumab 61 plus dacarbazine 61 visceral metastases 61 FIRMAGON 61 boosted protease inhibitor 61 immunohistochemical staining 61 antiandrogen 61 azacytidine 61 vidofludimus 61 blinded randomized placebo controlled 61 standard chemotherapy regimens 61 peritoneal cancer 61 refractory colorectal cancer 61 neoplasia 61 Phase III randomized controlled 61 subtrochanteric 61 multicenter Phase III 61 mycophenolate mofetil MMF 61 recurrent ovarian cancer 61 beta blocker therapy 61 perioperative morbidity 61 Randomized trials 61 NNRTI resistance 60 CBLC# 60 endocrine therapy 60 virologic responses 60 fludarabine 60 mcg kg 60 cediranib 60 oophorectomy 60 Elotuzumab 60 elotuzumab 60 docetaxel Injection Concentrate 60 Adjuvant therapy 60 ablative therapy 60 NCCTG 60 transthoracic 60 hormone therapy estrogen 60 cabazitaxel 60 MACCE 60 cytotoxic therapy 60 peg interferon 60 dose atorvastatin 60 R0 resection 60 PRECiSE 60 Cutaneous T 60 IFN α 60 fibrinolytic therapy 60 bilateral oophorectomy 60 cancer mCRC 60 morphometric vertebral fractures 60 HNSCC 60 HBeAg seroconversion 60 Pegasys ® 60 allogeneic transplant 60 intracoronary 60 resistant ovarian cancer 60 endoscopic resection 60 Carotid Revascularization Endarterectomy vs. 60 intensive lipid lowering 60 intratumoral 60 antiplatelet therapy 60 LHRH 60 dose regimens 60 thoracoscopic lobectomy 60 adjuvant hormonal therapy 60 progesterone receptor negative 60 HES CEL 60 zalutumumab 60 colorectal carcinoma 60 TNF antagonist 60 ara C 60 prospectively stratified 60 temozolomide 60 LHRH antagonists 60 Lymph node 60 taxane chemotherapy 60 aspirin clopidogrel 60 mTOR inhibitors 60 hormone receptor negative 60 HBeAg negative 60 exemestane 60 postoperative AF 60 renal cell carcinomas 60 invasive carcinomas 60 hormone receptor status 60 Epirubicin 60 metastatic colorectal carcinoma 60 Newly Diagnosed Multiple Myeloma 60 adjuvant systemic 60 dosing cohorts 60 Enzastaurin 60 virological failure 60 mutational status 60 SCCHN 60 interferon IFN 60 histologic subtype 60 bortezomib refractory 60 zoledronate 60 relapsed refractory 60 colon carcinoma 60 Cell Lymphoma 60 multiple myeloma MM 60 HCV genotype 60 postoperative mortality 60 taxane refractory 60 adalimumab Humira 60 APTIVUS 60 small lymphocytic lymphoma 60 cilostazol 60 invasive lobular carcinoma 60 adenomatous polyps 60 adrenalectomy 60 thromboembolic complications 60 Vicinium TM 60 coronary intervention 60 NATRECOR R 60 VcMP 60 Bortezomib 60 fibrinolysis 60 cyclophosphamide doxorubicin vincristine 60 achieved sustained virologic 60 transarterial 60 tumor regressions 60 epoetin beta 60 transurethral 60 Gynecologic Oncology Group 60 zoledronic acid 60 beam radiotherapy 60 p#HER# positive 60 pegfilgrastim 60 malignant pleural mesothelioma 60 multicenter Phase 60 Cisplatin 60 Acute Myocardial Infarction 60 hormonal therapy 60 pancreatic carcinoma 60 octreotide 60 GISTs 60 acute GvHD 60 CLARITY TIMI 60 solid organ transplantation 60 MADIT II 60 Teriflunomide 60 TMC# r 60 TKI therapy 60 Renal Cell Carcinoma RCC 60 SABCS 60 EGFR expressing mCRC 60 methotrexate therapy 60 abciximab 60 pharmacokinetics PK 60 afatinib 60 radioiodine therapy 60 FOLFIRINOX 60 Radiation Therapy SIRT 60 4mg/kg 60 sustained virologic response 60 urate lowering 60 Randomized Phase 60 PROSTVAC ® 60 ToGA 60 cinacalcet 60 syngeneic 60 endocrine responsive 60 thyroglobulin 60 YONDELIS 60 cTnI 60 Camptosar ® 60 prospective multicenter study 60 farletuzumab 60 lipid lowering therapy 60 preoperative 60 Xeloda ® 60 mcg albinterferon alfa 2b 60 ICD implantation 60 perioperatively 60 CIN2 +